Add BrightSurf on Google Email

Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes

Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.

SourceJAMA Network·JournalJAMA Network Open·DateJul 5, 2024

City of Hope study suggests changing the gut microbiome improves health outcomes for people newly diagnosed with metastatic kidney cancer

Researchers found that a live biotherapeutic product CBM588, when taken orally, can improve health outcomes in people with metastatic kidney cancer. The study, published in Nature Medicine, suggests that the agent may enhance effectiveness of FDA-approved cancer immunotherapies by adjusting the gut microbiome.

SourceCity of Hope·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateJun 28, 2024

Lowering fecal immunochemical test positivity threshold vs multitarget stool RNA testing for colorectal cancer screening

This study found that lowering the fecal immunochemical test positivity threshold can achieve comparable sensitivity and specificity to the multitarget stool RNA test without additional testing. The findings are similar to previous observations with multitarget stool DNA testing, suggesting a potentially simpler screening method.

SourceJAMA Network·JournalJAMA·DateJun 1, 2024

A long-term ketogenic diet accumulates aged cells in normal tissues, a UT Health San Antonio-led study shows

A new study led by UT Health San Antonio found that long-term ketogenic diets can induce senescence, or aged cells, in normal tissues, affecting heart and kidney function. However, an intermittent ketogenic diet regimen eliminated these pro-inflammatory effects.

SourceUniversity of Texas Health Science Center at San Antonio·JournalScience Advances·TypeExperimental study·DateMay 17, 2024

Aspirin vs placebo as adjuvant therapy for breast cancer

A randomized clinical trial of 3,020 patients with high-risk nonmetastatic breast cancer found daily aspirin therapy had no effect on breast cancer recurrence or survival in early follow-up. Aspirin should not be recommended as an adjuvant breast cancer treatment despite its potential benefits and wide availability

SourceJAMA Network·JournalJAMA·DateApr 29, 2024

New urine-based test detects high-grade prostate cancer, helping men avoid unnecessary biopsies

Researchers have developed a new urine-based test that identifies high-grade prostate cancer by analyzing 18 genes linked to the disease. The test, called MyProstateScore2.0, was shown to be nearly 100% correct at ruling out aggressive cancers and helped avoid up to 41% of unnecessary biopsies.

SourceMichigan Medicine - University of Michigan·JournalJAMA Oncology·TypeExperimental study·DateApr 18, 2024

Targeting vulnerability in B-cell development leads to novel drug combination for leukemia

Researchers at St. Jude Children's Research Hospital designed a combination therapy to effectively treat relapsed or resistant B-cell leukemia by targeting the developmental stages of cancer cells. The findings revealed that a protein called BCL-2 is a hidden vulnerability in asparaginase-resistant tumor cells.

SourceSt. Jude Children's Research Hospital·JournalCancer Cell·TypeExperimental study·DateApr 8, 2024

Whole breast ultrafractionation radiotherapy after breast-conserving surgery in early breast cancer had no severe toxicities and did not affect patient-reported outcome

A single-center study found that ultrahypofractionated whole breast irradiation after breast-conserving surgery had no severe toxicities and did not affect patient-reported outcomes. Most patients (83.9%) were diagnosed with pathological stage I disease, and cosmetic effects showed no obvious differences before and after treatment.

SourceHigher Education Press·JournalMalignancy Spectrum·TypeRandomized controlled/clinical trial·DateFeb 22, 2024

Evaluating the performance of AI-based large language models in radiation oncology

A new study evaluates AI algorithms for autocontouring prior to radiotherapy in head and neck cancer. OpenAI's GPT-4-turbo demonstrated the best performance, while Llama-2 models underperformed. The study highlights the potential of generative AI to revolutionize radiation oncology education and practice.

SourceMary Ann Liebert, Inc./Genetic Engineering News·JournalAI in Precision Oncology·TypeExperimental study·DateFeb 8, 2024

Epigenetic combination therapy could overcome treatment resistance in epithelioid sarcomas and rhabdoid tumors

Researchers have identified mechanisms of resistance to tazemetostat in epithelioid sarcoma and rhabdoid tumors, leading to the development of a combination therapy strategy. The therapy uses an epigenetic treatment approach to target specific mutations that drive cancer growth.

SourceMemorial Sloan Kettering Cancer Center·JournalCancer Discovery·TypeExperimental study·DateFeb 5, 2024